Novel combination therapy against metastatic and androgen-independent prostate cancer by using gefitinib, tamoxifen and etoposide

Murielle Mimeault, Ganesh Venkatraman, Sonny L. Johansson, Erik Moore, Jean Pierre Henichart, Patrick Depreux, Ming-Fong Lin, Surinder Kumar Batra

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

In this study, we evaluated, for the first time, the antiproliferative and cytotoxic effects induced by a combination of a selective epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, gefitinib, with other chemotherapeutic drugs including estrogen receptor-beta (ER-β) antagonist (tamoxifen) and topoisomerase II inhibitor (etoposide) on some metastatic prostate cancer (PC) cell lines. Immunohistochemial analyses revealed that EGFR expression was enhanced in 38% of primary prostatic adenocarcinomas (Gleason scores 4-10) as compared to the corresponding normal tissues of the same prostate gland from 32 PC patients. The RT-PCR and Western blot data have also indicated the higher expression levels of EGFR and ER-β transcripts and proteins in metastatic LNCaP, DU145 and PC3 cells relative to nonmalignant normal prostate cells. Moreover, the results from MTT and FACS analyses revealed that the drugs, alone or in combination at lower concentrations, inhibited the growth of 17β-estradiol (E2) plus EGF and serum-stimulated androgen-responsive LNCaP-C33 and androgen-independent LNCaP-C81, DU145 and PC3 cells. Importantly, the combined gefitinib, tamoxifen and etoposide also caused a higher rate of apoptotic death of PC cells as compared to single agents. The cytotoxic effects induced by these drugs in PC3 cells appear to be mediated through the accumulation of cellular ceramide and activation of caspase cascades via a mitochondrial pathway. These findings indicate that the combined use of inhibitors of EGF-EGFR and E2-ER-β signaling with etoposide, which act by increasing the cellular ceramide levels and caspase activity, represents a promising strategy for a more effective treatment of metastatic PC forms.

Original languageEnglish (US)
Pages (from-to)160-169
Number of pages10
JournalInternational Journal of Cancer
Volume120
Issue number1
DOIs
StatePublished - Jan 1 2007

Fingerprint

Etoposide
Tamoxifen
Androgens
Prostatic Neoplasms
Epidermal Growth Factor Receptor
Estrogen Receptor beta
Ceramides
Caspases
Epidermal Growth Factor
Prostate
Pharmaceutical Preparations
Topoisomerase II Inhibitors
Therapeutics
Neoplasm Grading
Protein-Tyrosine Kinases
Estradiol
Adenocarcinoma
Western Blotting
gefitinib
Cell Line

Keywords

  • Apoptotic death
  • Ceramide
  • EGF-EGFR system
  • ER-β
  • Growth inhibition
  • Prostate cancer

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Novel combination therapy against metastatic and androgen-independent prostate cancer by using gefitinib, tamoxifen and etoposide. / Mimeault, Murielle; Venkatraman, Ganesh; Johansson, Sonny L.; Moore, Erik; Henichart, Jean Pierre; Depreux, Patrick; Lin, Ming-Fong; Batra, Surinder Kumar.

In: International Journal of Cancer, Vol. 120, No. 1, 01.01.2007, p. 160-169.

Research output: Contribution to journalArticle

Mimeault, Murielle ; Venkatraman, Ganesh ; Johansson, Sonny L. ; Moore, Erik ; Henichart, Jean Pierre ; Depreux, Patrick ; Lin, Ming-Fong ; Batra, Surinder Kumar. / Novel combination therapy against metastatic and androgen-independent prostate cancer by using gefitinib, tamoxifen and etoposide. In: International Journal of Cancer. 2007 ; Vol. 120, No. 1. pp. 160-169.
@article{29bcb347b34d476b8580198f9988d32a,
title = "Novel combination therapy against metastatic and androgen-independent prostate cancer by using gefitinib, tamoxifen and etoposide",
abstract = "In this study, we evaluated, for the first time, the antiproliferative and cytotoxic effects induced by a combination of a selective epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, gefitinib, with other chemotherapeutic drugs including estrogen receptor-beta (ER-β) antagonist (tamoxifen) and topoisomerase II inhibitor (etoposide) on some metastatic prostate cancer (PC) cell lines. Immunohistochemial analyses revealed that EGFR expression was enhanced in 38{\%} of primary prostatic adenocarcinomas (Gleason scores 4-10) as compared to the corresponding normal tissues of the same prostate gland from 32 PC patients. The RT-PCR and Western blot data have also indicated the higher expression levels of EGFR and ER-β transcripts and proteins in metastatic LNCaP, DU145 and PC3 cells relative to nonmalignant normal prostate cells. Moreover, the results from MTT and FACS analyses revealed that the drugs, alone or in combination at lower concentrations, inhibited the growth of 17β-estradiol (E2) plus EGF and serum-stimulated androgen-responsive LNCaP-C33 and androgen-independent LNCaP-C81, DU145 and PC3 cells. Importantly, the combined gefitinib, tamoxifen and etoposide also caused a higher rate of apoptotic death of PC cells as compared to single agents. The cytotoxic effects induced by these drugs in PC3 cells appear to be mediated through the accumulation of cellular ceramide and activation of caspase cascades via a mitochondrial pathway. These findings indicate that the combined use of inhibitors of EGF-EGFR and E2-ER-β signaling with etoposide, which act by increasing the cellular ceramide levels and caspase activity, represents a promising strategy for a more effective treatment of metastatic PC forms.",
keywords = "Apoptotic death, Ceramide, EGF-EGFR system, ER-β, Growth inhibition, Prostate cancer",
author = "Murielle Mimeault and Ganesh Venkatraman and Johansson, {Sonny L.} and Erik Moore and Henichart, {Jean Pierre} and Patrick Depreux and Ming-Fong Lin and Batra, {Surinder Kumar}",
year = "2007",
month = "1",
day = "1",
doi = "10.1002/ijc.22268",
language = "English (US)",
volume = "120",
pages = "160--169",
journal = "International Journal of Cancer",
issn = "0020-7136",
publisher = "Wiley-Liss Inc.",
number = "1",

}

TY - JOUR

T1 - Novel combination therapy against metastatic and androgen-independent prostate cancer by using gefitinib, tamoxifen and etoposide

AU - Mimeault, Murielle

AU - Venkatraman, Ganesh

AU - Johansson, Sonny L.

AU - Moore, Erik

AU - Henichart, Jean Pierre

AU - Depreux, Patrick

AU - Lin, Ming-Fong

AU - Batra, Surinder Kumar

PY - 2007/1/1

Y1 - 2007/1/1

N2 - In this study, we evaluated, for the first time, the antiproliferative and cytotoxic effects induced by a combination of a selective epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, gefitinib, with other chemotherapeutic drugs including estrogen receptor-beta (ER-β) antagonist (tamoxifen) and topoisomerase II inhibitor (etoposide) on some metastatic prostate cancer (PC) cell lines. Immunohistochemial analyses revealed that EGFR expression was enhanced in 38% of primary prostatic adenocarcinomas (Gleason scores 4-10) as compared to the corresponding normal tissues of the same prostate gland from 32 PC patients. The RT-PCR and Western blot data have also indicated the higher expression levels of EGFR and ER-β transcripts and proteins in metastatic LNCaP, DU145 and PC3 cells relative to nonmalignant normal prostate cells. Moreover, the results from MTT and FACS analyses revealed that the drugs, alone or in combination at lower concentrations, inhibited the growth of 17β-estradiol (E2) plus EGF and serum-stimulated androgen-responsive LNCaP-C33 and androgen-independent LNCaP-C81, DU145 and PC3 cells. Importantly, the combined gefitinib, tamoxifen and etoposide also caused a higher rate of apoptotic death of PC cells as compared to single agents. The cytotoxic effects induced by these drugs in PC3 cells appear to be mediated through the accumulation of cellular ceramide and activation of caspase cascades via a mitochondrial pathway. These findings indicate that the combined use of inhibitors of EGF-EGFR and E2-ER-β signaling with etoposide, which act by increasing the cellular ceramide levels and caspase activity, represents a promising strategy for a more effective treatment of metastatic PC forms.

AB - In this study, we evaluated, for the first time, the antiproliferative and cytotoxic effects induced by a combination of a selective epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, gefitinib, with other chemotherapeutic drugs including estrogen receptor-beta (ER-β) antagonist (tamoxifen) and topoisomerase II inhibitor (etoposide) on some metastatic prostate cancer (PC) cell lines. Immunohistochemial analyses revealed that EGFR expression was enhanced in 38% of primary prostatic adenocarcinomas (Gleason scores 4-10) as compared to the corresponding normal tissues of the same prostate gland from 32 PC patients. The RT-PCR and Western blot data have also indicated the higher expression levels of EGFR and ER-β transcripts and proteins in metastatic LNCaP, DU145 and PC3 cells relative to nonmalignant normal prostate cells. Moreover, the results from MTT and FACS analyses revealed that the drugs, alone or in combination at lower concentrations, inhibited the growth of 17β-estradiol (E2) plus EGF and serum-stimulated androgen-responsive LNCaP-C33 and androgen-independent LNCaP-C81, DU145 and PC3 cells. Importantly, the combined gefitinib, tamoxifen and etoposide also caused a higher rate of apoptotic death of PC cells as compared to single agents. The cytotoxic effects induced by these drugs in PC3 cells appear to be mediated through the accumulation of cellular ceramide and activation of caspase cascades via a mitochondrial pathway. These findings indicate that the combined use of inhibitors of EGF-EGFR and E2-ER-β signaling with etoposide, which act by increasing the cellular ceramide levels and caspase activity, represents a promising strategy for a more effective treatment of metastatic PC forms.

KW - Apoptotic death

KW - Ceramide

KW - EGF-EGFR system

KW - ER-β

KW - Growth inhibition

KW - Prostate cancer

UR - http://www.scopus.com/inward/record.url?scp=33845458723&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33845458723&partnerID=8YFLogxK

U2 - 10.1002/ijc.22268

DO - 10.1002/ijc.22268

M3 - Article

C2 - 17013895

AN - SCOPUS:33845458723

VL - 120

SP - 160

EP - 169

JO - International Journal of Cancer

JF - International Journal of Cancer

SN - 0020-7136

IS - 1

ER -